Emerging roles of secreted phospholipase A2 enzymes: Lessons from transgenic and knockout mice

Biochimie

Volumn 92, Issue 6, 2010, Pages 561-582

  Murakami, Makoto ^a   Taketomi, Yoshitaka ^a   Girard, Christophe ^b   Yamamoto, Kei ^a   Lambeau, Gérard ^b  

^a TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^b CNRS   (France)

Author keywords

Asthma; Atherosclerosis; Inflammation; Lipid mediator; Phospholipase A2

Indexed keywords

A 002; LY 329722; METHYLINDOXAM; MUCIN 2; PHOSPHOLIPASE A2 GROUP IB; PHOSPHOLIPASE A2 GROUP II; PHOSPHOLIPASE A2 GROUP III; PHOSPHOLIPASE A2 GROUP V; PHOSPHOLIPASE A2 GROUP X; PHOSPHOLIPASE A2 INHIBITOR; PHOSPHOLIPASE A2 RECEPTOR; PLACEBO; PRAVASTATIN; SECRETORY PHOSPHOLIPASE A2; UNCLASSIFIED DRUG; VARESPLADIB;

ADULT RESPIRATORY DISTRESS SYNDROME; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ASTHMA; ATHEROSCLEROSIS; BACTERIAL IMMUNITY; CARCINOGENESIS; CLINICAL TRIAL; COLORECTAL CANCER; DIABETES MELLITUS; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG SPECIFICITY; DRUG TARGETING; ENZYME INHIBITION; FUNGUS IMMUNITY; GENE MUTATION; HEART INFARCTION; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; KNOCKOUT MOUSE; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RHEUMATOID ARTHRITIS; SEPTIC SHOCK; STOMACH ADENOCARCINOMA; TRANSGENIC MOUSE;

ANIMALS; BINDING SITES; HUMANS; ISOENZYMES; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MODELS, BIOLOGICAL; PHOSPHOLIPASES A2, SECRETORY; RECEPTORS, PHOSPHOLIPASE A2;

MAMMALIA; MUS;

EID: 77953269931     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2010.03.015     Document Type: Review

References (298)

1. Kudo I., Murakami M. Phospholipase A2 enzymes. Prostaglandins Other Lipid Mediat. 2002, 68-69:3-58.
2. Burke J.E., Dennis E.A. Phospholipase A2 structure/function, mechanism, and signaling. J. Lipid Res. 2009, (Suppl. 50):S237-S242.
3. Valentin E., Lambeau G. Increasing molecular diversity of secreted phospholipases A2 and their receptors and binding proteins. Biochim. Biophys. Acta 2000, 1488:59-70.
4. Murakami M., Kudo I. Diversity and regulatory functions of mammalian secretory phospholipases A2. Adv. Immunol. 2001, 77:163-194.
5. Lambeau G., Gelb M.H. Biochemistry and physiology of mammalian secreted phospholipases A2. Annu. Rev. Biochem. 2008, 77:495-520.
6. Kita Y., Ohto T., Uozumi N., Shimizu T. Biochemical properties and pathophysiological roles of cytosolic phospholipase A2s. Biochim. Biophys. Acta 2006, 1761:1317-1322.
7. Ghosh M., Tucker D.E., Burchett S.A., Leslie C.C. Properties of the Group IV phospholipase A2 family. Prog. Lipid Res. 2006, 45:487-510.
8. Wilkins W.P., Barbour S.E. Group VI phospholipases A2: homeostatic phospholipases with significant potential as targets for novel therapeutics. Curr. Drug Targets 2008, 9:683-697.
9. Hooks S.B., Cummings B.S. Role of Ca2+-independen t phospholipase A2 in cell growth and signaling. Biochem. Pharmacol. 2008, 76:1059-1067.
10. Cedars A., Jenkins C.M., Mancuso D.J., Gross R.W. Calcium-independent phospholipases in the heart: mediators of cellular signaling, bioenergetics, and ischemia- induced electrophysiologic dysfunction. J. Cardiovasc. Pharmacol. 2009, 53:277-289.
11. Kienesberger P.C., Oberer M., Lass A., Zechner R. Mammalian patatin domain containing proteins: a family with diverse lipolytic activities involved in multiple biological functions. J. Lipid Res. 2009, (Suppl. 50):S63-S68.
12. Arai H. Platelet-activating factor acetylhydrolase. Prostaglandins Other Lipid Mediat. 2002, 68-69:83-94.
13. McIntyre T.M., Prescott S.M., Stafforini D.M. The emerging roles of PAF acetylhydrolase. J. Lipid Res. 2009, (Suppl. 50):S255-S259.
14. Fisher A.B., Dodia C., Feinstein S.I., Ho Y.S. Altered lung phospholipid metabolism in mice with targeted deletion of lysosomal-type phospholipase A2. J. Lipid Res. 2005, 46:1248-1256.
15. Abe A., Hiraoka M., Wild S., Wilcoxen S.E., Paine R., Shayman J.A. Lysosomal phospholipase A2 is selectively expressed in alveolar macrophages. J. Biol. Chem. 2004, 279:42605-42611.
16. Duncan R.E., Sarkadi-Nagy E., Jaworski K., Ahmadian M., Sul H.S. Identification and functional characterization of adipose-specific phospholipase A2 (AdPLA). J. Biol. Chem. 2008, 283:25428-25436.
17. Bonventre J.V., Huang Z., Taheri M.R., O'Leary E., Li E., Moskowitz M.A., Sapirstein A. Reduced fertility and postischaemic brain injury in mice deficient in cytosolic phospholipase A2. Nature 1997, 390:622-625.
18. Uozumi N., Kume K., Nagase T., Nakatani N., Ishii S., Tashiro F., Komagata Y., Maki K., Ikuta K., Ouchi Y., Miyazaki J., Shimizu T. Role of cytosolic phospholipase A2 in allergic response and parturition. Nature 1997, 390:618-622.
19. Klivenyi P., Beal M.F., Ferrante R.J., Andreassen O.A., Wermer M., Chin M.R., Bonventre J.V. Mice deficient in group IV cytosolic phospholipase A2 are resistant to MPTP neurotoxicity. J. Neurochem. 1998, 71:2634-2637.
20. Bao S., Miller D.J., Ma Z., Wohltmann M., Eng G., Ramanadham S., Moley K., Turk J. Male mice that do not express group VIA phospholipase A2 produce spermatozoa with impaired motility and have greatly reduced fertility. J. Biol. Chem. 2004, 279:38194-38200.
21. Bao S., Jacobson D.A., Wohltmann M., Bohrer A., Jin W., Philipson L.H., Turk J. Glucose homeostasis, insulin secretion, and islet phospholipids in mice that overexpress iPLA2beta in pancreatic beta-cells and in i PLA2beta-null mice. Am. J. Physiol. Endocrinol. Metab. 2008, 294:E217-E229.
22. Moon S.H., Jenkins C.M., Mancuso D.J., Turk J., Gross R.W. Smooth muscle cell arachidonic acid release, migration, and proliferation are markedly attenuated in mice null forcalcium-independent phospholipase A2beta. J. Biol. Chem. 2008, 283:33975-33987.
23. Carper M.J., Zhang S., Turk J., Ramanadham S. Skeletal muscle group VIA phospholipase A2 (iPLA2beta): expression and role in fatty acid oxidation. Biochemistry 2008, 47:12241-12249.
24. Malik I., Turk J., Mancuso D.J., Montier L., Wohltmann M., Wozniak D.F., Schmidt R.E., Gross R.W., Kotzbauer P.T. Disrupted membrane homeostasis and accumulation of ubiquitinated proteins in a mouse model of infantile neuroaxonal dystro phy caused by PLA2G6 mutations. Am. J. Pathol. 2008, 172:406-416.
25. Ramanadham S., Yarasheski K.E., Silva M.J., Wohltmann M., Novack D.V., Christiansen B., Tu X., Zhang S., Lei X., Turk J. Age-related changes in bone morphology are accelerated in grou p VIA phospholipase A2 (iPLA2beta)-null mice. Am. J. Pathol. 2008, 172:868-881.
26. Morgan N.V., Westaway S.K., Morton J.E., Gregory A., Gissen P., Sonek S., Cangul H., Coryell J., Canham N., Nardocci N., Zorzi G., Pasha S., Rodriguez D., Desguerre I., Mubaidin A., Bertini E., Trembath R.C., Simonati A., Schanen C., Johnson C.A., Levinson B., Woods C.G., Wilmot B., Kramer P., Gitschier J., Maher E.R., Hayflick S.J. PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron. Nat. Genet. 2006, 38:752-754.
27. Mancuso D.J., Sims H.F., Han X., Jenkins C.M., Guan S.P., Yang K., Moon S.H., Pietka T., Abumrad N.A., Schlesinger P.H., Gross R.W. Genetic ablation of calcium-independent phospholipase A2 gamma leads toalterations in mitochondrial lipid metabolism and function resulting in a deficient mitochondrial bioenergetic phenotype. J. Biol. Chem. 2007, 282:34611-34622.
28. Mancuso D.J., Kotzbauer P., Wozniak D.F., Sims H.F., Jenkins C.M., Guan S., Han X., Yang K., Sun G., Malik I., Conyers S., Green K.G., Schmidt R.E., Gross R.W. Genetic ablation of calcium-independent phospholipase A2{gamma} leads to alterations in hippocampal cardiolipin content and molecular species distribution, mitochondrial degeneration, autophagy, and cognitive dysfunction. J. Biol. Chem. 2009, 284:35632-35644.
29. Akassoglou K., Malester B., Xu J., Tessarollo L., Rosenbluth J., Chao M.V. Brain-specific deletion of neuropathy target esterase/swisscheese results in neurodegeneration. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:5075-5080.
30. Moser M., Li Y., Vaupel K., Kretzschmar D., Kluge R., Glynn P., Buettner R. Placental failure and impaired vasculogenesis result in embryonic lethality for neuropathy target esterase-deficient mice. Mol. Cell. Biol. 2004, 24:1667-1679.
31. Muhlig-Versen M., da Cruz A.B., Tschape J.A., Moser M., Buttner R., Athenstaedt K., Glynn P., Kretzschmar D. Loss of Swiss cheese/neuropathy target esterase activity causes disruption of phosphatidylcholine homeostasis and neuronal and glial death in adult Drosophila. J. Neurosci. 2005, 25:2865-2873.
32. Rainier S., Bui M., Mark E., Thomas D., Tokarz D., Ming L., Delaney C., Richardson R.J., Albers J.W., Matsunami N., Stevens J., Coon H., Leppert M., Fink J.K. Neuropathy target esterase gene mutations cause motor neuron disease. Am. J. Hum. Genet. 2008, 82:780-785.
33. Romeo S., Kozlitina J., Xing C., Pertsemlidis A., Cox D., Pennacchio L.A., Boerwinkle E., Cohen J.C., Hobbs H.H. Genetic variation in PNPLA3 confers susce ptibility to nonalcoholic fatty liver disease. Nat. Genet. 2008, 40:1461-1465.
34. Haemmerle G., Lass A., Zimmermann R., Gorkiewicz G., Meyer C., Rozman J., Heldmaier G., Maier R., Theussl C., Eder S., Kratky D., Wagner E.F., Klingenspor M., Hoefler G., Zechner R. Defective lipolysis and altered energy metabolism in mice lacking adipose triglyceride lipase. Science 2006, 312:734-737.
35. Fischer J., Lefevre C., Morava E., Mussini J.M., Laforet P., Negre-Salvayre A., Lathrop M., Salvayre R. The gene en coding adipose triglyceride lipase (PNPLA2) is mutated in neutral lipid storage disease with myopathy. Nat. Genet. 2007, 39:28-30.
36. Koizumi H., Yamaguchi N., Hattori M., Ishikawa T.O., Aoki J., Taketo M.M., Inoue K., Arai H. Targeted disruption of intracellular type I platelet activating factor-acetylhydrolase catalytic subunits causes severe impairment in spermatogenesis. J. Biol. Chem. 2003, 278:12489-12494.
37. Kono N., Inoue T., Yoshida Y., Sato H., Matsusue T., Itabe H., Niki E., Aoki J., Arai H. Protection against oxidative stress-induced hepatic injury by intracellular type II platelet-activating factor acetylhydrolase by metabolism of oxidized phospholipids in vivo. J. Biol. Chem. 2008, 283:1628-1636.
38. Hase M., Tanaka M., Yokota M., Yamada Y. Reduction in the extent of atherosclerosis in apolipoprotein E-deficient mice induced by electroporation-mediated transfer of the human plasma platelet-activating factor acetylhydrolase gene into skeletal muscle. Prostaglandins Other Lipid Mediat. 2002, 70:107-118.
39. Quarck R., De Geest B., Stengel D., Mertens A., Lox M., Theilmeier G., Michiels C., Raes M., Bult H., Collen D., Van Veldhoven P., Ninio E., Holvoet P. Adenovirus-mediated gene transfer of human platelet-activating factor-acetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice. Circulation 2001, 103:2495-2500.
40. Wilensky R.L., Shi Y., Mohler E.R., Hamamdzic D., Burgert M.E., Li J., Postle A., Fenning R.S., Bollinger J.G., Hoffman B.E., Pelchovitz D.J., Yang J., Mirabile R.C., Webb C.L., Zhang L., Zhang P., Gelb M.H., Walker M.C., Zalewski A., Macphee C.H. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat. Med. 2008, 14:1059-1066.
41. Serruys P.W., Garcia-Garcia H.M., Buszman P., Erne P., Verheye S., Aschermann M., Duckers H., Bleie O., Dudek D., Botker H.E., von Birgelen C., D'Amico D., Hutchinson T., Zambanini A., Mastik F., van Es G.A., van der Steen A.F., Vince D.G., Ganz P., Hamm C.W., Wijns W., Zalewski A. Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 2008, 118:1172-1182.
42. Jaworski K., Ahmadian M., Duncan R.E., Sarkadi-Nagy E., Varady K.A., Hellerstein M.K., Lee H.Y., Samuel V.T., Shulman G.I., Kim K.H., de Val S., Kang C., Sul H.S. AdPLA ablation increases lipolysis and prevents obesity induced by high-fat feeding or leptin deficiency. Nat. Med. 2009, 15:159-168.
43. Wang Y., Feinstein S.I., Manevich Y., Ho Y.S., Fisher A.B. Peroxiredoxin 6 gene-targeted mice show increased lung injury with paraquat-induced oxidative stress. Antioxid. Redox Signal. 2006, 8:229-237.
44. Hiraoka M., Abe A., Lu Y., Yang K., Han X., Gross R.W., Shayman J.A. Lysosomal phospholipase A2 and phospholipidosis. Mol. Cell. Biol. 2006, 26:6139-6148.
45. Rouault M., Bollinger J.G., Lazdunski M., Gelb M.H., Lambeau G. Novel mammalian group XII secreted phospholipase A2 lacking enzymatic activity. Biochemistry 2003, 42:11494-11503.
46. Wang Y., Kowalski P.E., Thalmann I., Ornitz D.M., Mager D.L., Thalmann R. Otoconin-90, the mammalian otoconial matrix protein, contains two domains of homology to se cretory phospholipase A2. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:15345-15350.
47. Verpy E., Leibovici M., Petit C. Characterization of otoconin-95, the major protein of murine otoconia, provides insights into the formation of these inner ear biominerals. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:529-534.
48. Kowalski P.E., Freeman J.D., Mager D.L. Intergenic splicing between a HERV-H endogenous retrovirus and two adjacent human genes. Genomics 1999, 57:371-379.
49. Tischfield J.A., Xia Y.R., Shih D.M., Klisak I., Chen J., Engle S.J., Siakotos A.N., Winstead M.V., Seilhamer J.J., Allamand V., Gyapay G., Lusis A.J. Low-molecular-weight, calcium-dependent phospholipase A2 genes are linked and map to homologous chromosome regions in mouse and human. Genomics 1996, 32:328-333.
50. Valentin E., Singer A.G., Ghomashchi F., Lazdunski M., Gelb M.H., Lambeau G. Cloning and recombinant expression of human group IIF secreted phospholipase A2. Biochem. Biophys. Res. Commun. 2000, 279:223-228.
51. Singer A.G., Ghomashchi F., Le Calvez C., Bollinger J., Bezzine S., Rouault M., Sadilek M., Nguyen E., Lazdunski M., Lambeau G., Gelb M.H. Interfacial kinetic and binding properties of the complete set of human and mouse groups I, II, V, X, and XII secreted phospholipases A2. J. Biol. Chem. 2002, 277:48535-48549.
52. Gora S., Lambeau G., Bollinger J.G., Gelb M., Ninio E., Karabina S.A. The proinflammatory mediator platelet activating factor is an effective substrate for human group X secreted phospholipase A2. Biochim. Biophys. Acta 2006, 1761:1093-1099.
53. Mitsuishi M., Masuda S., Kudo I., Murakami M. Group V and X secretory phospholipase A2 prevents adenoviral infection in mammalian cells. Biochem. J. 2006, 393:97-106.
54. Mitsuishi M., Masuda S., Kudo I., Murakami M. Human group III phospholipase A2 suppresses adenovirus infection into host cells. Evidence that group III, V and X phospholipase A2s act on distinct cellular phospholipid molecular species. Biochim. Biophys. Acta 2007, 1771:1389-1396.
55. Fourcade O., Simon M.F., Viode C., Rugani N., Leballe F., Ragab A., Fournie B., Sarda L., Chap H. Secretory phospholipase A2 generates the novel lipid mediator lysophosphatidic acid in membrane microvesicles shed from activated cells. Cell 1995, 80:919-927.
56. Hanasaki K., Yamada K., Yamamoto S., Ishimoto Y., Saiga A., Ono T., Ikeda M., Notoya M., Kamitani S., Arita H. Potent modification of low density lipoprotein by group X secretory phospholipase A2 is linked to macrophage foam cell formation. J. Biol. Chem. 2002, 277:29116-29124.
57. Chabot S., Koumanov K., Lambeau G., Gelb M.H., Chignard M., Whitsett J.A., Touqui L. Inhibitory effects of surfactant protein A on surfactant phospholipid hydrolysis by secreted phospholipases A2. J. Immunol. 2003, 171:995-1000.
58. Karabina S.A., Brocheriou I., Le Naour G., Agrapart M., Durand H., Gelb M., Lambeau G., Ninio E. Atherogenic properties of LDL particles modified by human group X secreted phospholipase A2 on human endothelial cell function. Faseb J. 2006, 20:2547-2549.
59. Oorni K., Kovanen P.T. Lipoprotein modification by secretory phospholipase A(2) enzymes contributes to the initiation and progression of atherosclerosis. Curr. Opin. Lipidol. 2009, 20:421-427.
60. Lambeau G., Lazdunski M. Receptors for a growing family of secreted phospholipases A2. Trends Pharmacol. Sci. 1999, 20:162-170.
61. Valentin E., Lambeau G. What can venom phospholipases A2 tell us about the functional diversity of mammalian secreted phospholipases A2?. Biochimie 2000, 82:815-831.
62. Mounier C.M., Bon C., Kini R.M. Anticoagulant venom and mammalian secreted phospholipases A(2): protein- versus phospholipid-dependent mechanism of action. Haemostasis 2001, 31:279-287.
63. Pungercar J., Krizaj I. Understanding the molecular mechanism underlying the presynaptic toxicity of secreted phospholipases A2. Toxicon 2007, 50:871-892.
64. Seilhamer J.J., Randall T.L., Yamanaka M., Johnson L.K. Pancreatic phospholipase A2: isolation of the human gene and cDNAs from porcine pancreas and human lung. DNA 1986, 5:519-527.
65. Verheij H.M., Slotboom A.J., De Haas G. Structure and function of phospholipase A2. Rev. Physiol. Biochem. Pharmacol. 1981, 91:91-203.
66. Kudo I., Murakami M., Hara S., Inoue K. Mammalian non-pancreatic phospholipases A2. Biochim. Biophys. Acta 1993, 1170:217-231.
67. Richmond B.L., Boileau A.C., Zheng S., Huggins K.W., Granholm N.A., Tso P., Hui D.Y. Compensatory phospholipid digestion is required for cholesterol absorption in pancreatic phospholipase A (2)-deficient mice. Gastroenterology 2001, 120:1193-1202.
68. Huggins K.W., Boileau A.C., Hui D.Y. Protection against diet-induced obesity and obesity- related insulin resistance in Group 1B PLA2-deficient mice. Am. J. Physiol. Endocrinol. Metab. 2002, 283:E994-E1001.
69. Labonte E.D., Kirby R.J., Schildmeyer N.M., Cannon A.M., Huggins K.W., Hui D.Y. Group IB phospholipase A2-Mediated lysophospholipid absorption directly contributes to postprandial hyperglycemia. Diabetes 2006, 55:935-941.
70. Hui D.Y., Cope M.J., Labonte E.D., Chang H.T., Shao J., Goka E., Abousalham A., Charmot D., Buysse J. The phospholipase A(2) inhibitor methyl indoxam suppresses diet-induced obesity and glucose intolerance in mice. Br. J. Pharmacol. 2009, 157:1263-1269.
71. Valentin E., Ghomashchi F., Gelb M.H., Lazdunski M., Lambeau G. On the diversity of secreted phospholipases A2. Cloning, tissue distribution, and functional expression of two novel mouse group II enzymes. J. Biol. Chem. 1999, 274:31195-31202.
72. Mandal A.K., Zhang Z., Chou J.Y., Zimonjic D., Keck C.L., Popescu N., Mukherjee A.B. Molecular characterization of murine pancreatic phospholipase A(2). DNA Cell Biol. 2001, 20:149-157.
73. Kolko M., Prause J.U., Bazan N.G., Heegaard S. Human secretory phosp holipase A(2), group IB in normal eyes and in eye diseases. Acta Ophthalmol. Scand. 2007, 85:317-323.
74. Ottlecz A., Romero J.J., Lichtenberger L.M. Helicobacter infection and phospholipase A2 enzymes: effect of Helicobacter felis-infection on the expr ession and activity of sPLA2 enzymes in mouse stomach. Mol. Cell. Biochem. 2001, 221:71-77.
75. Huhtinen H.T., Gronroos J.M., Haapamaki M.M., Nevalainen T.J. Source of group II phospholipase A2 in gastric juice. Scand. J, Clin. Lab. Invest. 2002, 62:123-128.
76. Kramer R.M., Hession C., Johansen B., Hayes G., McGray P., Chow E.P., Tizard R., Pepinsky R.B. Structure and properties of a human non-pancreatic phospholipase A2. J. Biol. Chem. 1989, 264:5768-5775.
77. Seilhamer J.J., Pruzanski W., Vadas P., Plant S., Miller J.A., Kloss J., Johnson L.K. Cloning and recombinant expression of phospholipase A2 present in rheumatoid arthritic synovial fluid. J. Biol. Chem. 1989, 264:5335-5338.
78. Pruzanski W., Vadas P. Phos pholipase A2-a mediator between proximal and distal effectors of inflammation. Immunol. Today 1991, 12:143-146.
79. Murakami M., Nakatani Y., Atsumi G., Inoue K., Kudo I. Regulatory functions of phospholipase A2. Crit. Rev. Immunol. 1997, 17:225-283.
80. Nakano T., Ohara O., Teraoka H., Arita H. Glucocorticoids suppress group II phospholipase A2 production by blocking mRNA synthesis and post-transcriptional expression. J. Biol. Chem. 1990, 265:12745-12748.
81. Crowl R.M., Stoller T.J., Conroy R.R., Stoner C.R. Induction of phospholipase A2 gene expression in human hepatoma cells by mediators of the acute phase response. J. Biol. Chem. 1991, 266:2647-2651.
82. Oka S., Arita H. Inflammatory factors stimulate expression of group II phospholipaseA2 in rat cultured astrocytes. Two distinct pathways of the gene expression. J. Biol. Chem. 1991, 266:9956-9960.
83. Pfeilschifter J., Schalkwijk C., Briner V.A., Van Den Bosch H. Cytokine-stimulated secretion of group II phospholipase A2 by rat mesangial cells. Its contribution to arachidonic acid release and prostaglandin synthesis by cultured rat glomerular cells. J. Clin. Invest. 1993, 92:2516-2523.
84. Kuwata H., Yamamoto S., Miyazaki Y., Shimbara S., Nakatani Y., Suzuki H., Ueda N., Yamamoto S., Murakami M., Kudo I. Studies on a mechanism by which cytosolic phospholipase A2 regulates the expression and function of type IIA secretory phospholipase A2. J. Immunol. 2000, 165:4024-4031.
85. Couturier C., Brouillet A., Couriaud C., Koumanov K., B ereziat G., Andreani M. Interleukin 1beta induces type II-secreted phospholipase A(2) gene in vascular smooth muscle cells by a nuclear factor kappaB and peroxisome proliferator-activated receptor-mediated process. J. Biol. Chem. 1999, 274:23085-23093.
86. Peilot H., Rosengren B., Bondjers G., Hurt-Camejo E. Interferon-gamma induces secretory group IIA phospholipase A2 in human arterial smooth muscle cells. Involvement of cell differentiation, STAT-3 activation, and modulation by other cytokines. J. Biol. Chem. 2000, 275:22895-22904.
87. Massaad C., Paradon M., Jacques C., Salvat C., Bereziat G., Berenbaum F., Olivier J.L. Induction of secreted type IIA phospholipase A2 gene transcription by interleukin-1beta. Role of C/EBP factors. J. Biol. Chem. 2000, 275:22686-22694.
88. Akiba S., Hatazawa R., Ono K., Kitatani K., Hayama M., Sato T. Secretory phospholipase A2 mediates cooperative prostaglandin generation by growth factor and cytokine independently of preceding cytosolic phospholipase A2 expression i n rat gastric epithelial cells. J. Biol. Chem. 2001, 276:21854-21862.
89. Murakami M., Shimbara S., Kambe T., Kuwata H., Winstead M.V., Tischfield J.A., Kudo I. The functions of five distinct mammalian phospholipase A2s in regulating arachidonic acid re lease. Type IIA and type V secretory phospholipases A2 are functionally redundant and act in concert with cytosolic phospholipase A2. J. Biol. Chem. 1998, 273:14411-14423.
90. Murakami M., Kambe T., Shimbara S., Yamamoto S., Kuwata H., Kudo I. Functional association of type IIA secretory phospholipase A2 with the glycosylphosphatidylinositol-anchored heparan sulfate proteoglycan in the cyclooxygenase-2-mediated delayed prostanoid-biosynthetic pathway. J. Biol. Chem. 1999, 274:29927-29936.
91. Muraka mi M., Koduri R.S., Enomoto A., Shimbara S., Seki M., Yoshihara K., Singer A., Valentin E., Ghomashchi F., Lambeau G., Gelb M.H., Kudo I. Distinct arachidonate-releasing functions of mammalian secreted phospholipases A2 in fibroblastic and mastocytoma cells through heparan sulfate shuttling and external plasma membrane mechanisms. J. Biol. Chem. 2001, 276:10083-10096.
92. Kuwata H., Nakatani Y., Murakami M., Kudo I. Cytosolic phospholipase A2 is required for cytokine-induced expression of type IIA secretor y phospholipase A2 that mediates optimal cyclooxygenase-2-dependent delayed prostaglandin E2 generation in rat 3Y1 fibroblasts. J. Biol. Chem. 1998, 273:1733-1740.
93. Koduri R.S., Baker S.F., Snitko Y., Han S.K., Cho W., Wilton D.C., Gelb M.H. Action o f human group IIa secreted phospholipase A2 on cell membranes. Vesicle but not heparinoid binding determines rate of fatty acid release by exogenously added enzyme. J. Biol. Chem. 1998, 273:32142-32153.
94. Mounier C.M., Ghomashchi F., Lindsay M.R., James S., Singer A.G., Parton R.G., Gelb M.H. Arachidonic acid release from mammalian cells transfected with human groups IIA and X secreted phospholipase A2 occurs predominantly during the secretory process and with the involvement of cytosolic phospholipase A2-alpha. J. Biol. Chem. 2004, 279:25024-25038.
95. Atsumi G., Murakami M., Tajima M., Shimbara S., Hara N., Kudo I. The perturbed membrane of cells undergoing apoptosis is susceptible to type II secretory phospholipase A2 to liberate arachidonic acid. Biochim. Biophys. Acta 1997, 1349:43-54.
96. Snitko Y., Yoon E.T., Cho W. High specificity of human secretory class II phospholipase A2 for phosphatidic acid. Biochem. J. 1997, 321:737-741.
97. min-induced intestinal neoplasia. Cell 1995, 81:957-966.
98. Kennedy B.P., Payette P., Mudgett J., Vadas P., Pruzanski W., Kwan M., Tang C., Rancourt D.E., Cromlish W.A. A natural disruption of the secretory group II phospholipase A2 gene in inbred mouse strains. J. Biol. Chem. 1995, 270:22378-22385.
99. Wang T.C., Goldenring J.R., Dangler C., Ito S., Mueller A., Jeon W.K., Koh T.J., Fox J.G. Mice lacking secretory phospholipase A2 show altered apoptosis and differentiation with Helicobacter felis infection. Gastroenterology 1998, 114:675-689.
100. Papanikolaou A., Wang Q.S., Mulherkar R., Bolt A., Rosenberg D.W. Expression analysis of the group IIA secretory phospholipase A2 in mice with differential susceptibility to azoxymethane-induced colon tumorigenesis. Carcinogenesis 2000, 21:133-138.
101. Markova M., Koratkar R.A., Silverman K.A., Sollars V.E., MacPhee-Pellini M., Walters R., Palazzo J.P., Buchberg A.M., Siracusa L.D., Farber S.A. Diversity in secreted PLA2-IIA activity among inbred mouse strains that are resistant or susceptible to Apc Min/+ tumorigenesis. Oncogene 2005, 24:6450-6458.
102. Wong D.A., Kita Y., Uozumi N., Shimizu T. Discrete role for cytosolic phospholipase A(2)alpha in platelets: studies using single and double mutant mice of cytosolic and group IIA secretory phospholipase A(2). J. Exp. Med. 2002, 196:349-357.
103. Ishikawa S., Uozumi N., Shiibashi T., Izumi T., Fukayama M., Shimizu T., Watanabe J., Nogami S. Short report: lethal malaria in cytosolic phospholipase A2- and phospholipase A2IIA-deficient mice. Am. J. Trop. Med. Hyg. 2004, 70:645-650.
104. Cormier R.T., Hong K.H., Halberg R.B., Ha wkins T.L., Richardson P., Mulherkar R., Dove W.F., Lander E.S. Secretory phospholipase Pla2g2a confers resistance to intestinal tumorigenesis. Nat. Genet. 1997, 17:88-91.
105. Fijneman R.J., Bade L.K., Peham J.R., van de Wiel M.A., van Hinsbergh V.W., Meijer G.A., O'Sullivan M.G., Cormier R.T. Pla2g2a attenuates colon tumorigenesis in azoxymethane-treated C57BL/6 mice; expression studies reveal Pla2g2a target genes and pathways. Cell. Oncol. 2009, 31:345-356.
106. Fijneman R.J., Peham J.R., van de Wiel M.A., Meijer G.A., Matise I., Velcich A., Cormier R.T. Expression of Pla2g2a prevents carcinogenesis in Muc2-deficient mice. Cancer Sci. 2008, 99:2113-2119.
107. Riggins G.J., Markowitz S., Wilson J.K., Vogelstein B., Kinzler K.W. Absence of secretory ph ospholipase A2 gene alterations in human colorectal cancer. Cancer Res. 1995, 55:5184-5186.
108. Nimmrich I., Friedl W., Kruse R., Pietsch S., Hentsch S., Deuter R., Winde G., Muller O. Loss of the PLA2G2A gene in a sporadic colorectal tumor of a patien t with a PLA2G2A germline mutation and absence of PLA2G2A germline alterations in patients with FAP. Hum. Genet. 1997, 100:345-349.
109. Yanaru-Fujisawa R., Matsumoto T., Kukita Y., Nakamura S., Yao T., Hayashi K., Iida M. Impact of Phospholipase A2 group IIa gene polymorphism on phenotypic features of patients with familial adenomatous polyposis. Dis. Colon Rectum 2007, 50:223-231.
110. Leung S.Y., Chen X., Chu K.M., Yuen S.T., Mathy J., Ji J., Chan A.S., Li R., Law S., Troyanskaya O.G., Tu I.P., Wong J., So S., Botstein D., Brown P.O. Phospholipase A2 group IIA expression in gastric adenocarcinoma is associated with prolonged survival and less frequent metastasis. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:16203-16208.
111. Aggarwal A., Guo D.L., Hoshida Y., Yuen S.T., Chu K.M., So S., Boussioutas A., Chen X., Bowtell D., Aburatani H., Leung S.Y., Tan P. Topological and functional discovery in a gene coexpression meta-network of gastric cancer. Cancer Res. 2006, 66:232-241.
112. Sono shita M., Takaku K., Sasaki N., Sugimoto Y., Ushikubi F., Narumiya S., Oshima M., Taketo M.M. Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice. Nat. Med. 2001, 7:1048-1051.
113. Nakanishi M., Mont rose D.C., Clark P., Nambiar P.R., Belinsky G.S., Claffey K.P., Xu D., Rosenberg D.W. Genetic deletion of mPGES-1 suppresses intestinal tumorigenesis. Cancer Res. 2008, 68:3251-3259.
114. Park J.M., Kanaoka Y., Eguchi N., Aritake K., Grujic S., Materi A.M., Buslon V.S., Tippin B.L., Kwong A.M., Salido E., French S.W., Urade Y., Lin H.J. Hematopoietic prostaglandin D synthase suppresses intestinal adenomas in ApcMin/+ mice. Cancer Res. 2007, 67:881-889.
115. Murata T., Lin M.I., Aritake K., Matsumoto S., Narumiya S., Ozaki H., Urade Y., Hori M., Sessa W.C. Role of prostaglandin D2 receptor DP as a suppressor of tumor hyperpermeability and angiogenesis in vivo. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:20009-20014.
116. Dong Q., Patel M., Scott K.F., Graham G.G., Russell P.J., Sved P. Oncogenic action of phospholipase A2 in prostate cancer. Cancer Lett. 2006, 240:9-16.
117. Mirtti T., Laine V.J., Hiekkanen H., Hurme S., Rowe O., Nevalainen T.J., Kallajoki M., Alanen K. Group IIA phospholipase A as a prognostic marker in prostate cancer: relevance to clinicopathological variables and disease-specific mortality. Apmis 2009, 117:151-161.
118. Grass D.S., Felkner R.H., Chiang M.Y., Wallace R.E., Nevalainen T.J., Bennett C.F., Swanson M.E. Expression of humangroup II PLA2 in transgenic mice results in epidermal hyperplasia in the absence of inflammatory infiltrate. J. Clin. Invest. 1996, 97:2233-2241.
119. Mulherkar R., Kirtane B.M., Ramchandani A., Mansukhani N.P., Kannan S., Naresh K.N. Expression of enhancing factor/phospholipase A2 in skin results in abnormal epidermis and increased sensitivity to chemical carcinogenesis. Oncogene 2003, 22:1936-1944.
120. Nevalainen T.J., Graham G.G., Scott K.F. Antibacterial actions of secreted phospholipases A2. Review. Biochim. Biophys. Acta 2008, 1781:1-9.
121. Nevalainen T.J., Aho H.J., Peuravuori H. Secretion of group 2 phospholipase A2 by lacrimal glands. Invest. Ophthalmol. Vis. Sci. 1994, 35:417-421.
122. Qu X.D., Lehrer R.I. Secretory phospholipase A2 is the principal bactericide for staphylococci and other gram-positive bacteria in human tears. Infect. Immun. 1998, 66:2791-2797.
123. Takayama K., Hara S., Kudo I., Inoue K. Detection of 14-kDa group II phospholipase A2 in human seminal plasma. Biochem. Biophys. Res. Commun. 1991, 178:1505-1511.
124. Weinrauch Y., Abad C., Liang N.S., Lowry S.F., Weiss J. Mobilization of potent plasma bactericidal activity during systemic bacterial challenge. Role of group IIA phospholipase A2. J. Clin. Invest. 1998, 102:633-638.
125. Foreman-Wykert A.K., Weinrauch Y., Elsbach P., Weiss J. Cell-wall determinants of the bactericidal action of group IIA phospholipase A2 against Gram-positive bacteria. J. Clin. Invest. 1999, 103:715-721.
126. Laine V.J., Grass D.S., Nevalainen T.J. Protection by group II phospholipase A2 against Staphylococcus aureus. J. Immunol. 1999, 162:7402-7408.
127. Laine V.J., Grass D.S., Nevalainen T.J. Resistance of transgenic mice expressing human group II phospholipase A2 to Escherichia coli infection. Infect. Immun. 2000, 68:87-92.
128. Piris-Gimenez A., Paya M., Lambeau G., Chignard M., Mock M., Touqui L., Goossens P.L. In vivo protective role of human group IIA phospholipase A2 against experimental anthrax. J. Immunol. 2005, 175:6786-6791.
129. Koprivnjak T., Peschel A., Gelb M.H., Liang N.S., Weiss J.P. Role of charge properties of bacterial envelope in bactericidal action of human group IIA phospholipase A2 against Staphylococcus aureus. J. Biol. Chem. 2002, 277:47636-47644.
130. Gronroos J.O., Laine V.J., Janssen M.J., Egmond M.R., Nevalainen T.J. Bactericidal properties of group IIA and group V phospholipases A2. J. Immunol. 2001, 166:4029-4034.
131. Koduri R.S., Gronroos J.O., Laine V.J., Le Calvez C., Lambeau G., Nevalainen T.J., Gelb M.H. Bactericidal properties of human and murine groups I, II, V, X, and XII secreted phospholipases A2. J. Biol. Chem. 2002, 277:5849-5857.
132. Fenard D., Lambeau G., Valentin E., Lefebvre J.C., Lazdunski M., Doglio A. Secreted phosp holipases A2, a new class of HIV inhibitors that block virus entry into host cells. J. Clin. Invest. 1999, 104:611-618.
133. Romano M., Romano E., Bjorkerud S., Hurt-Camejo E. Ultrastructural localization of secretory type II phospholipase A2 in atherosclerotic and nonatherosclerotic regions of human arteries. Arterioscler. Thromb. Vasc. Biol. 1998, 18:519-525.
134. Ivandic B., Castellani L.W., Wang X.P., Qiao J.H., Mehrabian M., Navab M., Fogelman A.M., Grass D.S., Swanson M.E., de Beer M.C., de B eer F., Lusis A.J. Role of group II secretory phospholipase A2 in atherosclerosis: 1. Increased atherogenesis and altered lipoproteins in transgenic mice expressing group IIa phospholipase A2. Arterioscler. Thromb. Vasc. Biol. 1999, 19:1284-1290.
135. H urt-Camejo E., Camejo G., Peilot H., Oorni K., Kovanen P. Phospholipase A(2) in vascular disease. Circ. Res. 2001, 89:298-304.
136. Murakami M., Kudo I. New phospholipase A(2) isozymes with a potential role in atherosclerosis. Curr. Opin. Lipidol. 2003, 14:431-436.
137. Webb N.R., Bostrom M.A., Szilvassy S.J., van der Westhuyzen D.R., Daugherty A., de Beer F.C. Macrophage-expressed group IIA secretory phospholipase A2 increases atherosclerotic lesion formation in LDL receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2003, 23:263-268.
138. Webb N.R. Secretory phospholipase A2 enzymes in atherogenesis. Curr. Opin. Lipidol. 2005, 16:341-344.
139. Ghesquiere S.A., Hofker M.H., de Winther M.P. The role of phospholipases in lipid modification and atherosclerosis. Cardiovasc. Toxicol. 2005, 5:161-182.
140. Rosenson R.S., Hislop C., McConnell D., Elliott M., Stasiv Y., Wang N., Waters D.D. Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial. Lancet 2009, 373:649-658.
141. Rosenson R.S. Future role for selective phospholipase A2 inhibitors in the prevention of atherosclerotic cardiovascular disease. Cardiovasc. Drugs Ther. 2009, 23:93-101.
142. Kugiyama K., Ota Y., Takazoe K., Moriyama Y., Kawano H., Miyao Y., Sakamoto T., Soejima H., Ogawa H., Doi H., Sugiyama S., Yasue H. Circulating levels of secretory type II phospholipase A(2) predict coronary events in patients with coronary artery disease. Circulation 1999, 100:1280-1284.
143. Mallat Z., Steg P.G., Benessiano J., Tanguy M.L., Fox K.A., Collet J.P., Dabbous O.H., Henry P., Carruthers K.F., Dauphin A., Arguelles C.S., Masliah J., Hugel B., Montalescot G., Freyssinet J.M., Asselain B., Tedgui A. Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes. J. Am. Coll. Cardiol. 2005, 46:1249-1257.
144. Koenig W., Khuseyinova N. Lipoprotein-associated and secre tory phospholipase A2 in cardiovascular disease: the epidemiological evidence. Cardiovasc. Drugs Ther. 2009, 23:85-92.
145. Koenig W., Vossen C.Y., Mallat Z., Brenner H., Benessiano J., Rothenbacher D. Association between type II secretory phospholipase A2 plasma concentrations and activity and cardiovascular events in patients with coronary heart disease. Eur. Heart J. 2009, 30:2742-2748.
146. Hurt-Camejo E., Paredes S., Masana L., Camejo G., Sartipy P., Rosengren B., Pedreno J., Vallve J.C., Benito P., Wiklund O. Elevated levels of small, low-density lipoprotein with high affinity for arterial matrix components in patients with rheumatoid arthritis: possible contribution of phospholipase A2 to this atherogenic profile. Arthritis Rheum. 2001, 44:2761-2767.
147. Sartipy P., Johansen B., Gasvik K., Hurt-Camejo E. Molecular basis for the association of group IIA phospholipase A2 and decorin in human atherosclerotic lesions. Circ. Res. 2000, 86:707-714.
148. Ghesquiere S.A., Gijbels M.J., Anthonsen M., van Gorp P.J., van der Made I., Johansen B., Hofker M.H., de Winther M.P. Macrophage-specific overexpression of group IIa sPLA2 increases atherosclerosis and enhances collagen deposition. J. Lipid Res. 2005, 46:201-210.
149. Wooton-Kee C.R., Boya novsky B.B., Nasser M.S., de Villiers W.J., Webb N.R. Group V sPLA2 hydrolysis of low-density lipoprotein results in spontaneous particle aggregation and promotes macrophage foam cell formation. Arterioscler. Thromb. Vasc. Biol. 2004, 24:762-767.
150. Ros engren B., Peilot H., Umaerus M., Jonsson-Rylander A.C., Mattsson-Hulten L., Hallberg C., Cronet P., Rodriguez-Lee M., Hurt-Camejo E. Secretory phospholipase A2 group V: lesion distribution, activation by arterial proteoglycans, and induction in aorta by a Western diet. Arterioscler. Thromb. Vasc. Biol. 2006, 26:1579-1585.
151. Bostrom M.A., Boyanovsky B.B., Jordan C.T., Wadsworth M.P., Taatjes D.J., de Beer F.C., Webb N.R. Group V secretory phospholipase A2 promotes atherosclerosis: evidence from genetically altered mice. Arterioscler. Thromb. Vasc. Biol. 2007, 27:600-606.
152. Kimura-Matsumoto M., Ishikawa Y., Komiyama K., Tsuruta T., Murakami M., Masuda S., Akasaka Y., Ito K., Ishiguro S., Morita H., Sato S., Ishii T. Expression of secretory phospholipase A2s in human atherosclerosis development. Atherosclerosis 2008, 196:81-91.
153. Sato H., Kato R., Isogai Y., Saka G., Ohtsuki M., Taketomi Y., Yamamoto K., Tsutsumi K., Yamada J., Masuda S., Ishikawa Y., Ishii T., Kobayashi T., Ikeda K., Taguchi R., Hatakeyama S., Hara S., Kudo I., Itabe H., Murakami M. Analyses of group III secreted phospholipase A2 transgenic mice reveal potential participation of this enzyme in plasma lipoprotein modification, macrophage foam cell formation, and atherosclerosis. J. Biol. Chem. 2008, 283:33483-33497.
154. 2+-dependent phospholipase A2. J. Biol. Chem. 1994, 269:2365-2368.
155. Murak ami M., Kambe T., Shimbara S., Higashino K., Hanasaki K., Arita H., Horiguchi M., Arita M., Arai H., Inoue K., Kudo I. Different functional aspects of the group II subfamily (Types IIA and V) and type X secretory phospholipase A2s in regulating arachidonic acid release and prostaglandin generation. Implications of cyclooxygenase-2 induction and phospholipid scramblase-mediated cellular membrane perturbation. J. Biol. Chem. 1999, 274:31435-31444.
156. Han S.K., Kim K.P., Koduri R., Bittova L., Munoz N.M., Leff A.R., Wilton D.C., Gelb M.H., Cho W. Roles of Trp31 in high membrane binding and proinflammatory activity of human group V phospholipase A2. J. Biol. Chem. 1999, 274:11881-11888.
157. Kim K.P., Rafter J.D., Bittova L., Han S.K., Snitko Y., Munoz N.M., Leff A.R., Cho W. Mechanism of human group V phospholipase A2 (PLA2)-induced leukotriene biosynthesis in human neutrophils. A potential role of heparan sulfate binding in PLA2 internalization and degradation. J. Biol. Chem. 2001, 276:11126-11134.
158. Munoz N.M., Kim Y.J., Meliton A.Y., Kim K.P., Han S.K., Boetticher E., O'Leary E., Myou S., Zhu X., Bonventre J.V., Leff A.R., Cho W. Human group V phospholipase A2 induces group IVA phospholipase A2-independent cysteinyl leukotriene synthesis in human e osinophils. J. Biol. Chem. 2003, 278:38813-38820.
159. Kim Y.J., Kim K.P., Han S.K., Munoz N.M., Zhu X., Sano H., Leff A.R., Cho W. Group V phospholipase A2 induces leukotriene biosynthesis in human neutrophils through the activation of group IVA phospholipase A2. J. Biol. Chem. 2002, 277:36479-36488.
160. Wijewickrama G.T., Kim J.H., Kim Y.J., Abraham A., Oh Y., Ananthanarayanan B., Kwatia M., Ackerman S.J., Cho W. Systematic evaluation of transcellular activities of secretory phospholipases A2. High activity of group V phospholipases A2 to induce eicosanoid biosynthesis in neighboring inflammatory cells. J. Biol. Chem. 2006, 281:10935-10944.
161. Chen Y., Dennis E.A. Expression and characterization of human group V phospholipase A2. Biochim. Biophys. Acta 1998, 1394:57-64.
162. Pruzanski W., Lambeau G., Lazdunski M., Cho W., Kopilov J., Kuksis A. Differential hydrolysis of molecular species of lipoprotein phosphatidylcholine by groups IIA, V and X secretory phospholipases A2. Biochim. Biophys. Acta 2005, 1736:38-50.
163. Satake Y., Diaz B.L., Balestrieri B., Lam B.K., Kanaoka Y., Grusby M.J., Arm J.P. Role of group V phospholipase A2 in zymosan-induced eicosanoid generation and vascular permeability revealed by targeted gene disruption. J. Biol. Chem. 2004, 279:16488-16494.
164. Diaz B.L., Satake Y., Kikawada E., Balestrieri B., Arm J.P. Group V secretory phospholipase A2 amplifies the induction of cyclooxygenase 2 and delayed prostaglandin D2 generation in mouse bone marrow culture-derivedmast cells in a strain-dependent manner. Biochim. Biophys. Acta 2006, 1761:1489-1497.
165. Kikawada E., Bonventre J.V., Arm J.P. Group V secretory PLA2 regulates TLR2-dependent eicosanoid generation in mouse mast cells through amplification of ERK and c PLA2alpha activation. Blood 2007, 110:561-567.
166. Bingham C.r., Murakami M., Fujishima H., Hunt J.E., Austen K.F., Arm J.P. A heparin-sensitive phospholipase A2 and prostaglandin endoperoxide synthase-2 are functionally linked in the delayed phase ofprostaglandin D2 generation in mouse bone marrow-derived mast cells. J. Biol. Chem. 1996, 271:25936-25944.
167. Murakami M., Tada K., Nakajima K., Kudo I. Cyclooxygenase-2-dependent delayed prostaglandin D2 generation is initiated by nerve growth factor in rat peritoneal mast cells: its augmentation by extracellular type II secretory phospholipase A2. J. Immunol. 1997, 159:439-446.
168. Enomoto A., Murakami M., Valentin E., Lambeau G., Gelb M.H., Kudo I. Redundant and segregated functions of granule-a ssociated heparin-binding group II subfamily of secretory phospholipases A2 in the regulation of degranulation and prostaglandin D2 synthesis in mast cells. J. Immunol. 2000, 165:4007-4014.
169. Triggiani M., Giannattasio G., Calabrese C., Loffredo S., Granata F., Fiorello A., Santini M., Gelb M.H., Marone G. Lung mast cells are a source of secreted phospholipases A2. J. Allergy Clin. Immunol. 2009, 124:558-565.
170. Balestrieri B., Hsu V.W., Gilbert H., Leslie C.C., Han W.K., Bonventre J.V., Arm J.P. Group V secretory phospholipase A2 translocates to the phagosome after zymosan stimulation of mouse peritoneal macrophages and regulates phagocytosis. J. Biol. Chem. 2006, 281:6691-6698.
171. Balestrieri B., Maekawa A., Xing W., Gelb M.H., Katz H.R., Arm J.P. Group V secretory phospholipase A2 modulates phagosome maturation and regulates the innate immune response against Candida albicans. J. Immunol. 2009, 182:4891-4898.
172. Nevalainen T.J., Eerola L.I., Rintala E., Laine V.J., Lambeau G., Gelb M.H. Time-resolved fluoroimmunoassays of the complete set of secreted phospholipases A2 in human serum. Biochim. Biophys. Acta 2005, 1733:210-223.
173. Seeds M.C., Jones K.A., Duncan Hite R., Willingham M.C., Borgerink H.M., Woodruff R.D., Bowton D.L., Bass D.A. Cell-specific expression of group X and group V secretory phospholipases A(2) in human lung airway epithelial cells. Am. J. Respir. Cell. Mol. Biol. 2000, 23:37-44.
174. Masuda S., Murakami M., Mitsuishi M., Komiyama K., Ishikawa Y., Ishii T., Kudo I. Expression of secretory phospholipase A2 enzymes in lungs of humans with pneumonia and their potential prostaglandin-synthetic function in human lung-derived cells. Biochem. J. 2005, 387:27-38.
175. Birts C.N., Barton C.H., Wilton D.C. A catalytic ally independent physiological function for human acute phase protein group IIA phospholipase A2: cellular uptake facilitates cell debris removal. J. Biol. Chem. 2008, 283:5034-5045.
176. Matsuoka T., Hirata M., Tanaka H., Takahashi Y., Murata T., Kab ashima K., Sugimoto Y., Kobayashi T., Ushikubi F., Aze Y., Eguchi N., Urade Y., Yoshida N., Kimura K., Mizoguchi A., Honda Y., Nagai H., Narumiya S. Prostaglandin D2 as a mediator of allergic asthma. Science 2000, 287:2013-2017.
177. Shiraishi Y., Asano K., Niimi K., Fukunaga K., Wakaki M., Kagyo J., Takihara T., Ueda S., Nakajima T., Oguma T., Suzuki Y., Shiomi T., Sayama K., Kagawa S., Ikeda E., Hirai H., Nagata K., Nakamura M., Miyasho T., Ishizaka A. Cyclooxygenase-2/prostaglandin D2/CRTH2 pathway mediates double-stranded RNA-induced enhancement of allergic airway inflammation. J. Immunol. 2008, 180:541-549.
178. Nakata J., Kondo M., Tamaoki J., Takemiya T., Nohara M., Yamagata K., Nagai A. Augmentation of allergic inflammation in the airways of cycl ooxygenase-2-deficient mice. Respirology (Carlton, Vic.) 2005, 10:149-156.
179. Zeldin D.C., Wohlford-Lenane C., Chulada P., Bradbury J.A., Scarborough P.E., Roggli V., Langenbach R., Schwartz D.A. Airway inflammation and responsiveness in prostaglandin H synthase-deficient mice exposed to bacterial lipopolysaccharide. Am. J. Respir. Cell. Mol. Biol. 2001, 25:457-465.
180. Jaffar Z., Ferrini M.E., Buford M.C., Fitzgerald G.A., Roberts K. Prostaglandin I2-IP signaling blocks allergic pulmonary inflammation by preventing recruitment of CD4+ Th2 cells into the airways in a mouse model of asthma. J. Immunol. 2007, 179:6193-6203.
181. Kunikata T., Yamane H., Segi E., Matsuoka T., Sugimoto Y., Tanaka S., Tanaka H., Nagai H., Ichikawa A., Narumiya S. Suppression of allergic inflammation by the prostaglandin E receptor subtype EP3. Nat. Immunol. 2005, 6:524-531.
182. Irvin C.G., Tu Y.P., Sheller J.R., Funk C.D. 5-Lipoxygenase products are necessary for ovalbumin-induced airway responsiveness in mice. Am. J. Physiol. 1997, 272:L1053-L1058.
183. Kim D.C., Hsu F.I., Barrett N.A., Friend D.S., Grenningloh R., Ho I.C., Al-Garawi A., Lora J.M., Lam B.K., Austen K.F., Kanaoka Y. Cysteinyl leukotrienes regulate Th2 cell-dependent pulmonary inflammation. J. Immunol. 2006, 176:4440-4448.
184. Tager A.M., Bromley S.K., Medoff B.D., Islam S.A., Bercury S.D., Friedrich E.B., Carafone A.D., Gerszten R.E., Luster A.D. Leukotriene B4 receptor BLT1 mediates early effector T cell recruitment. Nat. Immunol. 2003, 4:982-990.
185. Levy B.D., De Sanctis G.T., Devchand P.R., Kim E., Ackerman K., Schmidt B.A., Szczeklik W., Drazen J.M., Serhan C.N. Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A(4). Nat. Med. 2002, 8:1018-1023.
186. Levy B.D., Kohli P., Gotlinger K., Haworth O., Hong S., Kazani S., Israel E., Haley K.J., Serhan C.N. Protectin D1 is generated in asthma and dampens airway inflammation and hyperresponsiveness. J. Immunol. 2007, 178:496-502.
187. Haworth O., Cernadas M., Yang R., Serhan C.N., Levy B.D. Resolvin E1 regulates interleukin 23, interferon-gamma and lipoxin A4 to promote the resolution of allergic airway inflammation. Nat. Immunol. 2008, 9:873-879.
188. Ishii S., Nagase T., Shindou H., Takizawa H., Ouchi Y., Shimizu T. Platelet-activating factor receptor develops airway hyperresponsiveness independently of airway inflammation in a murine asthma model. J. Immunol. 2004, 172:7095-7102.
189. Munoz N.M., Meliton A.Y., Arm J.P., Bonventre J.V., Cho W., Leff A.R. Deletion of secretory group V phospholipase A2 attenuates cell migration and airway hyperresponsiveness in immunosensitized mice. J. Immunol. 2007, 179:4800-4807.
190. Munoz N.M., Meliton A.Y., Meliton L.N., Dudek S.M., Leff A.R. Secretory group V phospholipase A2 regulates acute lung injury and neutrophilic inflammation caused by LPS in mice. Am. J. Physiol. Lung Cell. Mol. Physiol. 2009, 296:L879-L887.
191. Chilton F.H., Averill F.J., Hubbard W.C., Fonteh A.N., Triggiani M., Liu M.C. Antigen-induce d generation of lyso-phospholipids in human airways. J. Exp. Med. 1996, 183:2235-2245.
192. Touqui L., Alaoui-El-Azher M. Mammalian secreted phospholipases A2 and their pathophysiological significance in inflammatory diseases. Curr. Mol. Med. 2001, 1:739-754.
193. Arbibe L., Koumanov K., Vial D., Rougeot C., Faure G., Havet N., Longacre S., Vargaftig B.B., Bereziat G., Voelker D.R., Wolf C., Touqui L. Generation of lyso-phospholipids from surfactant in acute lung injury is mediated by type-II phosphol ipase A2 and inhibited by a direct surfactant protein A-phospholipase A2 protein interaction. J. Clin. Invest. 1998, 102:1152-1160.
194. Furue S., Mikawa K., Nishina K., Shiga M., Ueno M., Tomita Y., Kuwabara K., Teshirogi I., Ono T., Hori Y., Matsukawa A., Yoshinaga M., Obara H. Therapeutic time-window of a group IIA phospholipase A2 inhibitor in rabbit acute lung injury: correlation with lung surfactant protection. Crit. Care Med. 2001, 29:719-727.
195. Smart B.P., Oslund R.C., Walsh L.A., Gelb M.H. The first potent inhibitor of Mammalian group X secreted phospholipase A2: elucidation of sites for enhanced binding. J. Med. Chem. 2006, 49:2858-2860.
196. Hallstrand T.S., Chi E.Y., Singer A.G., Gelb M.H., Henderson W.R. Secreted phospholipase A 2 group X overexpression in asthma and bronchial hyperresponsiveness. Am. J. Respir. Crit. Care Med. 2007, 176:1072-1078.
197. Ohtsuki M., Taketomi Y., Arata S., Masuda S., Ishikawa Y., Ishii T., Takanezawa Y., Aoki J., Arai H., Yamamoto K., Kudo I., Murakami M. Transgenic expression of group V, but not group X, secreted phospholipase A2 in mice leads to neonatal lethality because of lung dysfunction. J. Biol. Chem. 2006, 281:36420-36433.
198. Curfs D.M., Ghesquiere S.A., Vergouwe M.N., van der Made I., Gijbels M.J., Greaves D.R., Verbeek J.S., Hofker M.H., de Winther M.P. Macrophage secretory phospholipase A2 group X enhances anti-inflammatory responses, promotes lipid accumulation, and contributes to aberrant lung pathology. J. Biol. Chem. 2008, 283:21640-21648.
199. Gesquiere L., Cho W., Subbaiah P.V. Role of group IIa and group V secretory phospholipases A(2) in the metabolism of lipoproteins. Substrate specificities of the enzymes and the regulation of their activities by sphingomyelin. Biochemistry 2002, 41:4911-4920.
200. Boyanovsky B.B., van der Westhuyzen D.R., Webb N.R. Group V secretory phospholipase A2-modified low density lipoprotein promotes foam cell formation by a SR-A- and CD36-independent process that involves cellular proteoglycans. J. Biol. Chem. 2005, 280:32746-32752.
201. Boyanovsky B.B., Shridas P., Simons M., van der Westhuyzen D.R., Webb N.R. Syndecan-4 mediates macrophage uptake of group V secretory phospholipase A2-modified LDL. J. Lipid Res. 2009, 50:641-650.
202. de Beer F.C., Webb N.R. Inflammation and atherosclerosis: group IIa and Group V sPLA2 are not redundant. Arterioscler. Thromb. Vasc. Biol. 2006, 26:1421-1422.
203. Rosengren B., Jonsson-Rylander A.C., Peilot H., Camejo G., Hurt-Camejo E. Distinctiveness of secretory phospholipase A2 group IIA and V suggesting unique roles in atherosclerosis. Biochim. Biophys. Acta 2006, 1761:1301-1308.
204. -/- mouse LDL in vitro predicts its atherogenic role in vivo. Arterioscler. Thromb. Vasc. Biol. 2009, 29:532-538.
205. Wootton P.T., Arora N.L., Drenos F., Thompson S.R., Cooper J.A., Stephens J.W., Hurel S.J., Hurt-Camejo E., Wiklund O., Humphries S.E., Talmud P.J. Tagging SNP haplotype analysis of the secretory PLA2-V gene, PLA2G5, shows strong association with LDL and oxLDL levels, suggesting functional distinction from sPLA2-IIA: results from the UDACS study. Hum. Mol. Genet. 2007, 16:1437-1444.
206. Pettersson C., Fogelstrand L., Rosengren B., Stahlman S., Hurt-Camejo E., Fagerberg B., Wiklund O. Increased lipolysis by secretory phospholipase A(2) group V of lipoproteins in diabetic dyslipidaemia. J. Intern. Med. 2008, 264:155-165.
207. H. Fraser, C. Hislop, R.M. Christie, H.L. Rick, C.A. Reidy, M.L. Chouinard, P.I. Eacho, K.E. Gould, J. Trias, Varespladib (A-002), a secretory phospholipase A2 inhibitor, reduces atherosclerosis and Aneurysm formation in ApoE-/- mice, J. Cardiovasc. Pharmacol. in press.
208. -/- mice between pravastatin and the sPLA2 inhibitor varespladib (A-002). J. Lipid Res. 2009, 50:623-629.
209. Kar akas M., Koenig W. Varespladib methyl, an oral phospholipase A2 inhibitor for the potential treatment of coronary artery disease. IDrugs 2009, 12:585-592.
210. Hamaguchi K., Kuwata H., Yoshihara K., Masuda S., Shimbara S., Oh-ishi S., Murakami M., Kudo I. Induction of distinct sets of secretory phospholipase A2 in rodents during inflammation. Biochim. Biophys. Acta 2003, 1635:37-47.
211. Masuda S., Murakami M., Ishikawa Y., Ishii T., Kudo I. Diverse cellular localizations of secretory phospholipase A2 enzymes in several human tissues. Biochim. Biophys. Acta 2005, 1736:200-210.
212. Cupillard L., Koumanov K., Mattéi M.G., Lazdunski M., Lambeau G. Cloning, chromosomal mapping, and expression of a novel human secretory phospholipase A2. J. Biol. Chem. 1997, 272:15745-15752.
213. Hanasaki K., Ono T., Saiga A., Morioka Y., Ikeda M., Kawamoto K., Higashino K., Nakano K., Yamada K., Ishizaki J., Arita H. Purified group X secretory phospholipase A2 induced prominent release of arachidonic acid from human myeloid leukemia cells. J. Biol. Chem. 1999, 274:34203-34211.
214. Morioka Y., Saiga A., Yokota Y., Suzuki N., Ikeda M., Ono T., Nakano K., Fujii N., Ishizaki J., Arita H., Hanasaki K. Mouse group X secretory phospholipase A2 induces a potent release of a rachidonic acid from spleen cells and acts as a ligand for the phospholipase A2 receptor. Arch. Biochem. Biophys. 2000, 381:31-42.
215. Thomas G. Furin at the cutting edge: from protein traffic to embryogenesis and disease. Nat. Rev. Mol. Cell. Biol. 2002, 3:753-766.
216. Seidah N.G., Mayer G., Zaid A., Rousselet E., Nassoury N., Poirier S., Essalmani R., Prat A. The activation and physiological functions of the proprotein convertases. Int. J. Biochem. Cell Biol. 2008, 40:1111-1125.
217. Masuda S., Murakami M., Takanezawa Y., Aoki J., Arai H., Ishikawa Y., Ishii T., Arioka M., Kudo I. Neuronal expression and neuritogenic action of group X secreted phospholipase A2. J. Biol. Chem. 2005, 280:23203-23214.
218. Pan Y.H., Yu B.Z., Singer A.G., Ghomashchi F., Lambeau G., Gelb M.H., Jain M.K., Bahnson B.J. Crystal structure of human group X secreted phospholipase A2. Electrostatically neutral interfacial surface targets zwitterionic membranes. J. Biol. Chem. 2002, 277:29086-29093.
219. Bezzine S., Koduri R.S., Valentin E., Murakami M., Kudo I., Ghomashchi F., Sadilek M., Lambeau G., Gelb M.H. Exogenously added human group X secreted phospholipase A2 but not the group IB, IIA, and V enzymes efficiently release arachidonic acid from adherent mammalian cells. J. Biol. Chem. 2000, 275:3179-3191.
220. Morioka Y., Ikeda M., Saiga A., Fujii N., Ishimoto Y., Arita H., Hanasaki K. Potential role of group X secretory phospholipase A2 in cyclooxygenase-2-dependent PGE2 formation during colon tumorigenesis. FEBS Lett. 2000, 487:262-266.
221. Schadow A., Scholz K., Lambeau G., Gelb M.H., Furstenberger G., Pfeilschifter J., Kaszkin M. Characterization of group X phospholipase A2 as the major enzyme secreted by human keratinocytes and its regulation by the phorbol ester TPA. J. Invest. Dermatol. 2001, 116:31-39.
222. Surrel F., Jemel I., Boilard E., Bollinger J.G., Payre C., Mounier C.M., Talvinen K.A., Laine V.J., Nevalainen T.J., Gelb M.H., Lambeau G. Group X phospholipase A2 stimulates the proliferation of colon cancer cells by producing various lipid mediators. Mol. Pharmacol. 2009, 76:778-790.
223. Henderson W.R., Chi E.Y., Bollinger J.G., Tien Y.T., Ye X., Castelli L., Rubtsov Y.P., Singer A.G., Chiang G.K., Nevalainen T., Rudensky A.Y., Gelb M.H. Importance of group X-secreted phospholipase A2 in allergen-induced airway inflammation and remodeling in a mouse asthma model. J. Exp. Med. 2007, 204:865-877.
224. Han W.K., Sapirstein A., Hung C.C., Alessandrini A., Bonventre J.V. Cross-talk between cytosolic phospholipase A2 alpha (cPLA2 alpha) and secretory phospholipase A2 (sPLA2) in hydrogen peroxide-induced arachidonic acid release in murine mesangial cells: sPLA2 regulates cPLA2 alpha activity that is responsible for arachidonic acid release. J. Biol. Chem. 2003, 278:24153-24163.
225. Saiga A., Uozumi N., Ono T., Seno K., Ishimoto Y., Arita H., Shimizu T., Hanasaki K. Group X secretory phospholipase A2 can induce arachidonic acid release and eicosanoid production without activation of cytosolic phospholipase A2 alpha. Prostaglandins Other Lipid Mediat. 2005, 75:79-89.
226. Serhan C.N., Chiang N., Van Dyke T.E. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat. Rev. Immunol. 2008, 8:349-361.
227. Degousee N., Ghomashchi F., Stefanski E., Singer A., Smart B.P., Borregaard N., Reithmeier R., Lindsay T.F., Lichtenberger C., Reinisch W., Lambeau G., Arm J., Tischfield J., Gelb M.H., Rubin B.B. Groups IV, V and X phospholipases A2 in human neutrophils. Role in eicosanoid production and gram negative bacterial phospholipid hydrolysis. J. Biol. Chem. 2002, 277:5061-5073.
228. Fujioka D., Saito Y., Kobayashi T., Yano T., Tezuka H., Ishimoto Y., Suzuki N., Yokota Y., Nakamura T., Obata J.E., Kanazawa M., Kawabata K., Hanasaki K., Kugiyama K. Reduction in myocardial ischemia/reperfusion injury in group X secretory phospholipase A2-deficient mice. Circulation 2008, 117:2977-2985.
229. Solodkin-Szaingurten I., Levy R., Hadad N. Differential behavior of sPLA2-V and s PLA2-X in human neutrophils. Biochim. Biophys. Acta 2007, 1771:155-163.
230. Kim J.O., Chakrabarti B.K., Guha-Niyogi A., Louder M.K., Mascola J.R., Ganesh L., Nabel G.J. Lysis of human immunodeficiency virus type 1 by a specific secreted human phospholipase A2. J. Virol. 2007, 81:1444-1450.
231. Singh D.K., Gesquiere L.R., Subbaiah P.V. Role of sphingomyelin and ceramide in the regulation of the activity and fatty acid specificity of group V secretory phospholipase A2. Arch. Biochem. Biophys. 2007, 459:280-287.
232. Ishimoto Y., Yamada K., Yamamoto S., Ono T., Notoya M., Hanasaki K. Group V and X secretory phospholipase A2s-induced modification of high-density lipoprotein linked to the reduction of its antiatherogenic functions. Biochim. Biophys. Acta 2003, 1642:129-138.
233. Gora S., Perret C., Jemel I., Nicaud V., Lambeau G., Cambien F., Ninio E., Blankenberg S., Tiret L., Karabina S.A. Molecular and functional characterization of polymorphisms in the secreted phospholipase A2 group X gene: relevance to coronary artery disease. J. Mol. Med. 2009, 87:723-733.
234. Masuda S., Murakami M., Matsumoto S., Eguchi N., Urade Y., Lambeau G., Gelb M.H., Ishikawa Y., Ishii T., Kudo I. Localization of various secretory phospholipase A2 enzymes in male reproductive organs. Biochim. Biophys. Acta 2004, 1686:61-76.
235. Eerola L.I., Surrel F., Nevalainen T.J., Gelb M.H., Lambeau G., Laine V.J. Analysis of expression of secreted phospholipases A2 in mouse tissues at protein and mRNA levels. Biochim. Biophys. Acta 2006, 1761:745-756.
236. Roldan E.R., Shi Q.X. Sperm phospholipases and acrosomal exocytosis. Front. Biosci. 2007, 12:89-104.
237. Osterstrom A., Dimberg J., Fransen K., Soderkvist P. Expression of cytosolic and group X secretory phospholipaseA(2) genes in human colorectal adenocarcinomas. Cancer Lett. 2002, 182:175-182.
238. Mounier C.M., Wendum D., Greenspan E., Flejou J.F., Rosenberg D.W., Lambeau G. Distinct expression pattern of the full set of secreted phospholipases A2 in human colore ctal adenocarcinomas: sPLA2-III as a biomarker candidate. Br. J. Cancer 2008, 98:587-595.
239. Takaku K., Sonoshita M., Sasaki N., Uozumi N., Doi Y., Shimizu T., Taketo M.M. Suppression of intestinal polyposis in ApcDelta 716 knockout mice by an additio nal mutation in the cytosolic phospholipase A2 gene. J. Biol. Chem. 2000, 275:34013-34016.
240. Valentin E., Ghomashchi F., Gelb M.H., Lazdunski M., Lambeau G. Novel human secreted phospholipase A2 with homology to the group III bee venom enzyme. J. Biol. Chem. 2000, 275:7492-7496.
241. Murakami M., Masuda S., Shimbara S., Bezzine S., Lazdunski M., Lambeau G., Gelb M.H., Matsukura S., Kokubu F., Adachi M., Kudo I. Cellular arachidonate-releasing function of novel classes of secretory phospholipase A2s (groups III and XII). J. Biol. Chem. 2003, 278:10657-10667.
242. Murakami M., Masuda S., Shimbara S., Ishikawa Y., Ishii T., Kudo I. Cellular distribution, post-translational modification, and tumorigenic potential of human group III secreted phospholi pase A2. J. Biol. Chem. 2005, 280:24987-24998.
243. Masuda S., Yamamoto K., Hirabayashi T., Ishikawa Y., Ishii T., Kudo I., Murakami M. Human group III secreted phospholipase A2 promotes neuronal outgrowth and survival. Biochem. J. 2008, 409:429-438.
244. Sato H., Taketomi Y., Isogai Y., Masuda S., Kobayashi T., Yamamoto K., Murakami M. Group III secreted phospholipase A2 transgenic mice spontaneously develop inflammation. Biochem. J. 2009, 421:17-27.
245. Chen J., Engle S.J., Seilhamer J.J., T ischfield J.A. Cloning and characterization of novel rat and mouse low molecular weight Ca2+-dependent phospholipases A2 containing 16 cysteines. J. Biol. Chem. 1994, 269:23018-23024.
246. Chen J., Shao C., Lazar V., Srivastava C.H., Lee W.H., Tischfield J.A. Localization of group IIc low molecular weight phospholipase A2 mRNA to meiotic cells in the mouse. J. Cell. Biochem. 1997, 64:369-375.
247. Valentin E., Koduri R.S., Scimeca J.-C., Carle G., Gelb M.H., Lazdunski M., Lambeau G. Cloning and recombinan t expression of a novel mouse secreted phospholipase A2. J. Biol. Chem. 1999, 274:19152-19160.
248. Ishizaki J., Suzuki N., Higashino K., Yokota Y., Ono T., Kawamoto K., Fujii N., Arita H., Hanasaki K. Cloning and characterization of novel mouse and hum an secretory phospholipases A2. J. Biol. Chem. 1999, 274:24973-24979.
249. Golik M., Cohen-Zinder M., Loor J.J., Drackley J.K., Band M.R., Lewin H.A., Weller J.I., Ron M., Seroussi E. Accelerated expansion of group IID-like phospholipase A2 genes in Bos taurus. Genomics 2006, 87:527-533.
250. Shakhov A.N., Rubtsov A.V., Lyakhov I.G., Tumanov A.V., Nedospasov S.A. SPLASH (PLA2IID), a novel member of phospholipase A2 family, is associated with lymphotoxin deficiency. Genes Immun. 2000, 1:191-199.
251. von Allmen C.E., Schmitz N., Bauer M., Hinton H.J., Kurrer M.O., Buser R.B., Gwerder M., Muntwiler S., Sparwasser T., Beerli R.R., Bachmann M.F. Secretory phospholipase A2-IID is an effector molecule of CD4+CD25+ regulatory T cells. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:11673-11678.
252. Lindbom J., Ljungman A.G., Tagesson C. Interferon gamma-induced gene expression of the novel secretory phospholipase A2 type IID in human monocyte-derived macrophages is inhibited by lipopolysaccharide. Inflammation 2005, 29:108-117.
253. Takabatake N., Sata M., Inoue S., Shibata Y., Abe S., Wada T., Machiya J., Ji G., Matsuura T., Takeishi Y., Muramatsu M., Kubota I. A novel polymorphism in secretory phospholipase A2-IID is associated with body weight loss in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2005, 172:1097-1104.
254. Igarashi A., Shibata Y., Yamauchi K., Osaka D., Takabatake N., Abe S., Inoue S., Kimura T., Yamaguchi Y., Ishizaki J., Hanasaki K., Kubota I. Gly80Ser polymorphism of phospholipase A2-IID is associated with cytokine inducibility in A549 cells. Respiration; International Review Thoracic Diseases 2009, 78:312-321.
255. Suzuki N., Ishizaki J., Yokota Y., Higashino K., Ono T., Ikeda M., Fujii N., Kawamoto K., Hanasaki K. Structures, enzymatic properties, and expression of novel human and mouse secretory phospholipases A2. J. Biol. Chem. 2000, 275:5785-5793.
256. Murakami M., Yoshihara K., Shimbara S., Lambeau G., Gelb M.H., Singer A.G., Sawada M., Inagaki N., Nagai H., Ishihara M., Ishikawa Y., Ishii T., Kudo I. Cellular arachidonate-releasing function and inflammation-associated expression of group IIF secretory phospholipase A2. J. Biol. Chem. 2002, 277:19145-19155.
257. Wijewickrama G.T., Albanese A., Kim Y.J., Oh Y.S., Murray P.S., Takayanagi R., Tobe T., Masuda S., Murakami M., Kudo I., Ucker D.S., Murray D., Cho W. Unique membrane interaction mode of group IIF phospholipase A2. J. Biol. Chem. 2006, 281:32741-32754.
258. Gelb M.H., Valentin E., Ghoma shchi F., Lazdunski M., Lambeau G. Cloning and recombinant expression of a structurally novel human secreted phospholipase A2. J. Biol. Chem. 2000, 275:39823-39826.
259. Ho I.C., Arm J.P., Bingham C.O., Choi A., Austen K.F., Glimcher L.H. A novel group of phopholipase A2 preferentially expressed in Th2 cells. J. Biol. Chem. 2001, 276:18321-18326.
260. Huhtinen H.T., Gronroos J.O., Gronroos J.M., Uksila J., Gelb M.H., Nevalainen T.J., Laine V.J. Antibacterial effects of human group IIA and group XIIA pho spholipase A2 against Helicobacter pylori in vitro. Apmis 2006, 114:127-130.
261. Munoz-Sanjuan I., Brivanlou A.H. Induction of ectopic olfactory structures and bone morphogenetic protein inhibition by Rossy, a group XII secreted phospholipase A2. Mol. Cell. Biol. 2005, 25:3608-3619.
262. Zhao X., Yang H., Yamoah E.N., Lundberg Y.W. Gene targeting reveals the role of Oc90 as the essential organizer of the otoconial organic matrix. Dev. Biol. 2007, 304:508-524.
263. Zhao X., Jones S.M., Yamoah E.N., Lundberg Y.W. Otoconin-90 deletion leads to imbalance but normal hearing: a comparison with other otoconia mutants. Neuroscience 2008, 153:289-299.
264. Pote K.G., Hauer C.R.I., Michel H., Shabanowitz J., Hunt D.F., Kretsinger R.H. Otoconin-22, the major protein of aragonitic frog otoconia, is a homolog of phospholipase A2. Biochemistry 1993, 32:5017-5024.
265. Yaoi Y., Onda T., Hidaka Y., Yajima S., Suzuki M., Tanaka S. Developmental expression of otoconin-22 in the bullfrog endolymphatic sac and in nerear. J. Histochem. Cytochem. 2004, 52:663-670.
266. Petko J.A., Millimaki B.B., Canfield V.A., Riley B.B., Levenson R. Otoc1: a novel otoconin-90 ortholog required for otolith mineralization in zebrafish. Dev. Neurobiol. 2008, 68:209-222.
267. Boilard E., Bourgoin S.G., Bernatchez C., Poubelle P.E., Surette M.E. Interaction of low molecular weight group IIA phospholipase A2 with apoptotic human T cells: role of heparan sulfate proteoglycans. Faseb J. 2003, 17:1068-1080.
268. Hanasaki K., Arita H. Phospholipase A2 receptor: a regulator of biological functions of secretory phospholipase A2. Prostaglandins Other Lipid Mediat. 2002, 68-69:71-82.
269. Lizano S., Domont G., Perales J. Natural phospholipase A2 myotoxin inhibitor proteins from snakes, mammals and plants. Toxicon 2003, 42:963-977.
270. Triggiani M., Granata F., Giannattasio G., Marone G. Secretory phospholipases A2 in inflammatory and allergic diseases: not just enzymes. J. Allergy Clin. Immunol. 2005, 116:1000-1006.
271. Fujis awa D., Yamazaki Y., Lomonte B., Morita T. Catalytically inactive phospholipase A2 homologue binds to vascular endothelial growth factor receptor-2 via a C-terminal loop region. Biochem. J. 2008, 411:515-522.
272. Saegusa J., Akakura N., Wu C.Y., Hoogland C., Ma Z., Lam K.S., Liu F.T., Takada Y.K., Takada Y. Pro-inflammatory secretory phospholipase A2 type IIA binds to integrins alphavbeta3 and alpha4beta1 and induces proliferation of monocytic cells in an integrin-dependent manner. J. Biol. Chem. 2008, 283:26107-26115.
273. de Paula R.C., Castro H.C., Rodrigues C.R., Melo P.A., Fuly A.L. Structural and pharmacological features of phospholipases A2 from snake venoms. Protein Pept. Lett. 2009, 16:899-907.
274. Cintra-Francischinelli M., Pizzo P., Rodrigues-Simioni L., Ponce-Soto L.A., Rossetto O., Lomonte B., Gutierrez J.M., Pozzan T., Montecucco C. Calcium imaging of muscle cells treated with snake myotoxins reveals toxin synergism and presence of acceptors. Cell. Mol. Life Sci. 2009, 66:1718-1728.
275. Fayard J.M., Tessier C., Pageaux J.F., Lagarde M., Laugier C. Nuclear location of PLA2-I in proliferative cells. J. Cell. Sci. 1998, 111:985-994.
276. Beck S., Lambeau G., Scholz-Pedretti K., Gelb M.H., Janssen M.J., Edwards S.H., Wilton D.C., Pfeilschifter J., Kaszkin M. Potentiation of TNFalpha -induced sPLA2-IIA expression in mesangial cells by an autocrine loop involving secreted phospholipase A2 and PPARalpha activation. J. Biol. Chem. 2003, 278:29799-29812.
277. Martin R., Hernandez M., Ibeas E., Fuentes L., Salicio V., Arnes M., Nieto M.L. Secreted phospholipase A2-IIA modulates key regulators of proliferation on astrocytoma cells. J. Neurochem. 2009, 111:988-999.
278. Lambeau G., Schmid-Alliana A., Lazdunski M., Barhanin J. Identification and purification of a very high affinity binding protein for toxic phospholipases A2 in skeletal muscle. J. Biol. Chem. 1990, 265:9526-9532.
279. Llorca O. Extended and bent conformations of the mannose receptor family. Cell. Mol. Life Sci. 2008, 65:1302-1310.
280. Engelholm L.H., Ingvarsen S., Jurgensen H.J., Hillig T., Madsen D.H., Nielsen B.S., Behrendt N. The collagen receptor uPARAP/Endo180. Front. Biosci. 2009, 14:2103-2114.
281. Rouault M., Le Calvez C., Boilard E., Surrel F., Singer A., Ghomashchi F., Bezzine S., Scarzello S., Bollinger J., Gelb M.H., Lambeau G. Recombinant production and properties of binding of the full set of mouse secreted phospholipases A2 to the mouse M-type receptor. Biochemistry 2007, 46:1647-1662.
282. Lambea u G., Ancian P., Barhanin J., Lazdunski M. Cloning and expression of a membrane receptor for secretory phospholipases A2. J. Biol. Chem. 1994, 269:1575-1578.
283. Ancian P., Lambeau G., Mattéi M.G., Lazdunski M. The human 180-kDa receptor for secretory ph ospholipases A2. Molecular cloning, identification of a secreted soluble form, expression, and chromosomal localization. J. Biol. Chem. 1995, 270:8963-8970.
284. West A.P., Herr A.B., Bjorkman P.J. The chicken yolk sac IgY receptor, a functional eq uivalent of the mammalian MHC-related Fc receptor, is a phospholipase A2 receptor homolog. Immunity 2004, 20:601-610.
285. Fisher A.B., Dodia C., Chander A., Beers M.F., Bates S.R. Inhibition of Trimeresurus flavoviridis phospholipase A2 by lung surfactant protein A (SP-A). Biochim. Biophys. Acta 1994, 1211:256-262.
286. Okumura K., Ohno A., Nishida M., Hayashi K., Ikeda K., Inoue S. Mapping the region of the alpha-type phospholipase A2 inhibitor responsible for its inhibitory activity. J. Biol. Chem. 2005, 280:37651-37659.
287. Zvaritch E., Lambeau G., Lazdunski M. Endocytic properties of the M-type 180-kDa receptor for secretory phospholipases A2. J. Biol. Chem. 1996, 271:250-257.
288. Hanasaki K., Yokota Y., Ishizaki J., Itoh T., Arita H. Resi stance to endotoxic shock in phospholipase A2 receptor-deficient mice. J. Biol. Chem. 1997, 272:32792-32797.
289. Augert A., Payre C., de Launoit Y., Gil J., Lambeau G., Bernard D. The M-type receptor PLA2R regulates senescence through the p53 pathway. EMBO Rep. 2009, 10:271-277.
290. Kim H.J., Kim K.S., Kim S.H., Baek S.H., Kim H.Y., Lee C., Kim J.R. Induction of cellular senescence by secretory phospholipase A2 in human dermal fibroblasts through an ROS-mediated p53 pathway. J. Gerontol. A. Biol. Sci. Med. Sci. 2009, 64:351-362.
291. Beck L.H., Bonegio R.G., Lambeau G., Beck D.M., Powell D.W., Cummins T.D., Klein J.B., Salant D.J. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N. Engl. J. Med. 2009, 361:11-21.
292. Waite M. Handbook of Lipid Research: The Phospholipases 1987, 111-241. Plenum Press, New York. D.J. Hanahan (Ed.).
293. Verger R., Ferrato F., Mansbach C.M., Pieroni G. Novel intestinal phospholipase A2: purification and some molecular characteristics. Biochemistry 1982, 21:6883-6889.
294. Stefanski E., Pruzanski W., Sternby B., Vadas P. Purification of a soluble phospholipase A2 from synovial fluid in rheumatoid arthritis. J. Biochem. 1986, 100:1297-1303.
295. Forst S., Weiss J., Elsbach P., Maraganore J.M., Reardon I., Heinrikson R.L. Structural and functional properties of a phospholipase A2 purified from an inflammatory exudate. Biochemistry 1986, 25:8381-8385.
296. Hayakawa M., Kudo I., Tomita M., Nojima S., Inoue K. The primary structure of rat platelet phospholipase A2. J. Biochem. 1988, 104:767-772.
297. Reid R.C. Inhibitors of secretory phospholipase A2 group IIA. Curr. Med. Chem. 2005, 12:3011-3026.
298. E. Boilard, Y. Lai, K. Larabee, B. Balestrieri, F. Ghomashchi, D. Fujioka, R. Gobezie, J.S. Coblyn, M.E. Weinblatt, E.M. Massarotti, T.S. Thornhill, M. Divangahi, H. Remold, G. Lambeau, M.H. Gelb, J.P. Arm, D.M. Lee, A novel anti-inflammatory role for secretory phospholipase A2 in immune complex-mediated arthritis, Embo Mol. Med. in press.